Tech Company Financing Transactions
Synageva BioPharma Funding Round
Synageva BioPharma, based in Lexington, raised $25 million from Baker Brothers Investments, New Leaf Venture Partners and private investors.
Transaction Overview
Company Name
Announced On
3/21/2011
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Baker Brothers Investments (Felix Baker)
New Leaf Venture Partners (Srini Akkaraju)
Proceeds Purpose
In addition to initiating the global clinical studies for SBC-102, Synageva continues to expand the network of physicians and medical professionals that will be instrumental in developing this program and the company's other rare disease therapeutic candidates.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
128 Spring Street 520
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Synageva BioPharma's goal is to improve the lives of patients with rare and ultra rare diseases (diseases that affect less than 200,000 and 10,000 patients respectively) by providing access to breakthrough protein therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanj Patel
Chief Financial Officer
Carsten Boess
Chief Medical Officer
Anthony Quinn
VP - General Counsel
Stephen Mahoney
VP - Operations
Glen Williams
VP - Regulatory Affairs
Mark Goldberg
VP - Regulatory Affairs
Mark Hayes
Browse more venture capital transactions:
Prev: 3/21/2011: 8thBridge venture capital transaction
Next: 3/21/2011: StellaService venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs